TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Cold Spring Harbor Laboratory researchers report that activating PPARD in immune cells helped engineered CAR T cells slow or stop tumor growth in experimental models. The findings, published in Nature Immunology, have not been tested as a treatment in patients, and the protein may have different effects depending on the cell type in which it is active.
Researchers at Cold Spring Harbor Laboratory report that activating PPARD in immune cells helped engineered CAR T cells slow or stop tumor growth in experimental models of colorectal cancer and other tumors. The findings, published in Nature Immunology, point to a possible way to strengthen immunotherapy, but the approach has not been shown to work in patients.
PPARD, or peroxisome proliferator-activated receptor delta, is a protein that regulates genes involved in cellular processes, including how cells use fat for energy. The researchers studied mice with colorectal cancer and found that PPARD’s effects differed by cell type: cancer cells can use the protein to support their activity, while activating it in immune cells shifted the tumor environment toward an immune attack, according to the study.
The team then activated PPARD in CAR T cells, immune cells engineered to recognize and attack cancer. In tests against human colorectal cancer, the modified cells slowed or stopped tumor growth across several experimental settings. Those included patient-derived organoids, cultured cancer cells and cancer cells implanted in mice. These are preclinical models, not clinical trials.
The researchers also reported promising results in experimental models of breast cancer, ovarian cancer and melanoma. The source report does not provide patient outcome data or show that PPARD activation is safe or effective as a treatment in people.
A Possible Boost for CAR T Cells
The findings offer a potential strategy for improving how immune cells perform inside tumors. CAR T-cell therapies are already used for certain cancers, but this study addresses whether changing the cells’ energy use could make them more effective against solid tumors such as colorectal cancer. That possibility may matter for patients whose cancers respond poorly to existing treatments, though this research does not establish a new therapy or show that it will benefit those patients.
The work also highlights a complication in targeting proteins linked to cancer: the effect can depend on which cells are affected. PPARD may support cancer-cell activity while helping immune cells fight tumors when activated in those immune cells. Any future treatment would need to preserve that distinction and establish a safe way to apply the approach.
As an affiliate, we earn on qualifying purchases.
Why Researchers Targeted Cell Metabolism
The study grew from the idea that a cell’s metabolic state can shape what it does. PPARD helps regulate fat use, and the team investigated whether changing that process could improve the functional fitness of immune cells. CSHL Assistant Professor Semir Beyaz said the researchers suspected that cancer cells and immune cells might be subject to similar metabolic constraints.
Colorectal cancer was the initial focus. The source report describes it as the leading cause of cancer-related death among people under 50 and notes that some patients have limited options when chemotherapy and immunotherapy fail. That burden helps explain the researchers’ interest, but the study’s results remain experimental. The team is also investigating whether immune-cell fitness might be relevant to endometriosis, a separate condition; that work is not evidence that PPARD activation treats it.
“We hypothesized that the fitness determinants of cancer and our immune cells may not be so different.”
— Semir Beyaz, CSHL assistant professor
Patient Testing Has Not Begun
No patient results are reported in the source material. It remains unclear whether PPARD-activated CAR T cells can be produced safely, retain their activity in people, or improve outcomes compared with existing approaches. The report does not specify a clinical-trial timetable, dosing strategy, or potential risks. It is also not clear how broadly the findings across different cancer models will translate to human disease.
The protein’s contrasting roles make cell-specific effects a central issue: activating PPARD in immune cells produced a different result from its role in cancer cells. The research does not establish how a future treatment could reliably target immune cells without also affecting tumors or other tissues.
Further Tests Before Any Treatment
The immediate next step is further research to test the approach and clarify its safety and effects before any use in patients. The source report says Beyaz’s laboratory is investigating possible applications beyond cancer, including endometriosis, but gives no timeline or clinical plans. Until human studies are reported, PPARD activation should be understood as a research strategy tested in laboratory and animal models, not an available cancer treatment.
Key Questions
What is PPARD?
PPARD is a protein that regulates genes involved in cellular processes, including how cells use fat for energy. The study examined its effects in cancer cells and immune cells.
Did the researchers test the approach in patients?
No patient testing is described. The reported results came from organoids, cultured cancer cells and mice, so effectiveness and safety in people remain unknown.
Which cancers were included in the experiments?
The team focused on colorectal cancer and also reported results in experimental models of breast cancer, ovarian cancer and melanoma.
Does activating PPARD help cancer or fight it?
The reported effect depended on the cell type. Cancer cells can use PPARD to support their activity, while activating it in immune cells helped CAR T cells attack tumors in the study’s experimental models.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
